Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27881880 | 0.93 | TAS1R3 (0.58) | TAS1R3TAS1R1ALDH1A1MAPTKDM4E | |
| SCHEMBL1829682 | 0.85 | LMNA (0.58) | TAS1R3TAS1R1ALDH1A1KDM4EHDAC6 | |
| SCHEMBL5520763 | 0.85 | HDAC1 (0.50) | TAS1R3TAS1R1ALDH1A1MAPTKDM4E | |
| SCHEMBL5784044 | 0.84 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL5782189 | 0.81 | KMT2A (0.54) | TAS1R3TAS1R1ALDH1A1MAPTHDAC6 | |
| SCHEMBL30522592 | 0.80 | ATM (0.67) | TAS1R3TAS1R1ATMHDAC8HDAC6 | |
| SCHEMBL1754131 | 0.80 | ATM (0.67) | TAS1R3TAS1R1ATMHDAC8HDAC6 | |
| SCHEMBL28736404 | 0.79 | ALDH1A1 (0.56) | TAS1R3TAS1R1ALDH1A1MAPTKDM4E | |
| SCHEMBL28736403 | 0.79 | ALDH1A1 (0.56) | TAS1R3TAS1R1ALDH1A1MAPTKDM4E | |
| SCHEMBL1828343 | 0.79 | TAS1R3 (0.52) | TAS1R3TAS1R1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102791716-B | 2,5,7-replaces oxazole pyrimidine derivatives | SAI NUOFEI (FR) | 2016-05-11 | — | — | CN | disclosed |
| US-8785439-B2 | 2,5,7-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| CN-102159582-B | Oxazolopyrimidines as edg-1 receptor agonists | SANOFI AVENTIS | 2014-05-07 | — | — | CN | disclosed |
| EP-2523961-B1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130137685-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| EP-2318415-B1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI SA (FR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2523961-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| CN-102159582-A | Oxazolopyrimidines as edg-1 receptor agonists | SANOFI AVENTIS | 2011-08-17 | — | — | CN | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2011086075-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-2318415-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006704-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137685-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, UNG, CDK2 | TAS1R3 2442/4885TAS1R1 2007/4885ALDH1A1 39/4885 |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | EDNRA, OXGR1, EDF1 | TAS1R3 807/4885TAS1R1 410/4885ALDH1A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.